Business Context and Reporting Period
Company: EyePoint Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 5, 2020
Principal Executive Offices: Watertown, MA
Trading Symbol: EYPT (Nasdaq)
This filing reports the entry into a material definitive agreement regarding a new equity financing mechanism.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, or debt metrics. The filing focuses exclusively on the authorization of a potential equity offering.
- Maximum Offering Size: Up to $25.0 million in aggregate offering price.
- Instrument: Common Stock, par value $0.001 per share.
- Sales Agent: Cantor Fitzgerald & Co.
- Commission: 3.0% of gross proceeds from each sale.
Material Changes
On August 5, 2020, the Company entered into a Controlled Equity Offering SM Sales Agreement. This agreement allows the Company to offer and sell shares of its common stock from time to time through Cantor Fitzgerald as an "at-the-market" offering. This represents a new liquidity facility for the Company, distinct from prior periods which did not include this specific sales agreement.
Guidance, Outlook, and Risks
Management Commentary: The Company has no obligation to sell any shares under the agreement and retains the right to suspend offers or terminate the agreement at any time. Sales will be made based on the Company's instructions and market conditions.
Risks and Contingencies:
- Dilution: Future sales of shares will result in dilution to existing shareholders.
- Market Conditions: The ability to sell shares depends on market conditions and the Company's discretion.
- Costs: The Company will incur a 3.0% commission on gross proceeds.
Investor Verification Checklist
- Verify the current share price to assess potential dilution impact from a $25.0 million offering.
- Review the attached Exhibit 1.1 (Sales Agreement) for specific terms regarding termination and indemnification.
- Check subsequent filings (e.g., 10-Q or 10-K) to determine if any shares have actually been sold under this agreement and the net proceeds received.
- Confirm the Company's current cash position to understand the necessity of this financing facility.